Viking Therapeutics

205 articles about Viking Therapeutics

• Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

  4/28/2021

  Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2021,

• Viking Therapeutics to Report Financial Results for First Quarter 2021 on April 28, 2021

  4/21/2021

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the first quarter 2021, after the market close on Wednesday, April 28, 2021.

• Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference

  4/7/2021

   Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian , Ph.D., will deliver a corporate presentation as part of the 20 th Annual Needham Virtual Healthcare Conference

• Viking Therapeutics to Participate at Upcoming Investor Conferences

  3/4/2021

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in three upcoming investor conferences.

• Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

  2/17/2021

  Conference call scheduled for 4:30 p.m. ET today - Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Continues to Enroll - Phase 1 Trial Evaluating VK0214 Ongoing; Expect to Initiate Proof-of-Concept Trial in X-ALD Patients Mid-2021 - Balance Sheet Remains Strong; Year-End Cash Approximately $250 Million

• Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2020 on February 17, 2021

  2/10/2021

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the fourth quarter and year-end 2020, after the market close on Wednesday, February 17, 2021.

• 

  BioSpace Movers & Shakers, Jan. 8

  1/8/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Viking Therapeutics Announces Senior Management Team Appointments

  1/6/2021

  Greg Zante Promoted to Chief Financial Officer and Marianne Mancini Promoted to Chief Operating Officer

• Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference

  1/5/2021

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2021 Conference.

• 

  Viking Therapeutics’ NASH Therapy Shows Major Reduction of Liver Fat and LDL Cholesterol

  11/19/2020

  Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, SVP of finance.

• Viking Therapeutics to Present at Stifel Healthcare Conference 2020

  11/10/2020

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian , Ph.D., will deliver a corporate presentation as part of the Stifel Healthcare Conference 202

• Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  10/28/2020

  Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2020,

• Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020

  10/21/2020

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2020, after the market close on Wednesday, October 28, 2020.

• Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214

  9/9/2020

  First-in-human clinical trial of novel, selective thyroid receptor ß agonist for X-ALD

• Viking Therapeutics to Participate in Upcoming Investor Conferences - Sep 02, 2020

  9/2/2020

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in four upcoming investor conferences.

• Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020

  8/28/2020

  VK2809-Treated Patients Maintain Durable, Statistically Significant Liver Fat Reductions at Week 16, Four Weeks Following Last Study Dose

• Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020

  8/20/2020

  Oral Presentation to Highlight New Efficacy Data Measured at Week 16 and Additional Week 12 Efficacy Data Stratified by Baseline Characteristics and Risk Factors

• Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  7/29/2020

  Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2020,

• Viking Therapeutics to Participate in Upcoming Investor Conferences - July 28, 2020

  7/28/2020

  Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in two upcoming investor conferences.

• Viking Therapeutics to Report Financial Results for Second Quarter 2020 on July 29, 2020

  7/22/2020

  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2020, after the market close on Wednesday, July 29, 2020.